Literature DB >> 32476955

High incidence of venous thromboembolism but not of coronary artery disease in granulomatosis with polyangiitis in first years after diagnosis.

Anna Borowiec1, Małgorzata Hadzik-Błaszczyk1, Ilona Kowalik1, Tomasz Rusinowicz1, Renata Krupa1, Jan Jankowski1, Piotr Kandyba1, Ewa Józefik1, Anna Gawałkiewicz1, Katarzyna Życińska1.   

Abstract

Objectives: Granulomatosis with polyangiitis (GPA), previously known as Wegener's granulomatosis, is one of antineutrophil cytoplasmic autoantibody (ANCA) - associated vasculitis. In patients with GPA an increased incidence of venous thromboembolism (VTE), mainly during active disease, has been described. The aim of the present study was to assess the incidence of VTE and its relation with classic risk factors for atherosclerosis, presence of coronary artery disease (CAD), echocardiographic parameters and laboratory findings in GPA patients.
Methods: The group of consecutive patients with GPA were followed in the study. In all patients echocardiography and laboratory tests were performed.
Results: Ninety six patients with GPA were followed for mean 3 years. In 16 patients (16.6%) VTEs occurred in association with GPA, of which 56% occurred 6 months before or one year after diagnosis of GPA. Classic risk factors for atherosclerosis were present in 77 patients (80.2%) at some moment during follow-up. In patients with VTE there were larger right ventricle diameter (p=0.041) and higher right ventricle systolic pressure (p=0.022) observed. VTEs occurred significantly less frequently in patients treated with cyclophosphamide (p=0.049). In this study group VTE occurred more frequently than CAD: 16 (16.7%) vs. 4 (4.2%); p=0,0049. Patients with VTE were younger than those with CAD (p=0.053) and had higher levels of ANCA-PR 3 (p=0.016). Conclusions: Patients with granulomatosis with polyangiitis in first years after diagnosis have higher risk of venous thromboembolism than coronary artery disease. This finding is probably related to hypercoagulability induced by the disease and its therapy. Copyright:
© 2020.

Entities:  

Keywords:  coronary artery disease; granulomatosis with polyangiitis; vasculitis; venous thromboembolism

Mesh:

Substances:

Year:  2019        PMID: 32476955      PMCID: PMC7247083          DOI: 10.36141/svdld.v36i3.8088

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  16 in total

1.  Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Sven Weidner; Syrus Hafezi-Rachti; Harald D Rupprecht
Journal:  Arthritis Rheum       Date:  2006-02-15

2.  Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study.

Authors:  Matthew D Morgan; Jennifer Turnbull; Umut Selamet; Manvir Kaur-Hayer; Peter Nightingale; Charles J Ferro; Caroline O S Savage; Lorraine Harper
Journal:  Arthritis Rheum       Date:  2009-11

3.  Thrombosis in small and medium-sized pulmonary arteries in Wegener's granulomatosis: a confocal laser scanning microscopy study.

Authors:  Alfredo Nicodemos Cruz Santana; Alexandre Muxfeldt Ab'Saber; Walcy Rosolio Teodoro; Vera Luiza Capelozzi; Carmen Silvia Valente Barbas
Journal:  J Bras Pneumol       Date:  2010 Nov-Dec       Impact factor: 2.624

4.  Venous thromboembolic events in systemic vasculitis.

Authors:  Pavel Novikov; Egor Makarov; Sergey Moiseev; Alexey Meshkov; Leonid Strizhakov
Journal:  Ann Rheum Dis       Date:  2014-11-07       Impact factor: 19.103

5.  Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study.

Authors:  Peter A Merkel; Grace H Lo; Janet T Holbrook; Andrea K Tibbs; Nancy B Allen; John C Davis; Gary S Hoffman; W Joseph McCune; E William St Clair; Ulrich Specks; Robert Spiera; Michelle Petri; John H Stone
Journal:  Ann Intern Med       Date:  2005-04-19       Impact factor: 25.391

6.  A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.

Authors:  Ravi Suppiah; Andrew Judge; Rajbir Batra; Oliver Flossmann; Lorraine Harper; Peter Höglund; M Kassim Javaid; David Jayne; Chetan Mukhtyar; Kerstin Westman; John C Davis; Gary S Hoffman; W Joseph McCune; Peter A Merkel; E William St Clair; Philip Seo; Robert Spiera; John H Stone; Raashid Luqmani
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

7.  Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis.

Authors:  Annelies E Berden; Sarah L Nolan; Hannah L Morris; Rogier M Bertina; Dianhdra D Erasmus; E Christiaan Hagen; Donal P Hayes; Nico H van Tilburg; Jan A Bruijn; Caroline O S Savage; Ingeborg M Bajema; Peter Hewins
Journal:  J Am Soc Nephrol       Date:  2010-09-16       Impact factor: 10.121

8.  High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients.

Authors:  Y Allenbach; R Seror; C Pagnoux; L Teixeira; P Guilpain; L Guillevin
Journal:  Ann Rheum Dis       Date:  2008-11-17       Impact factor: 19.103

9.  Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis.

Authors:  Mikkel Faurschou; Lene Mellemkjaer; Inge Juul Sorensen; Bjarne Svalgaard Thomsen; Lene Dreyer; Bo Baslund
Journal:  Arthritis Rheum       Date:  2009-04

10.  High risk of pulmonary embolism and deep venous thrombosis but not of stroke in granulomatosis with polyangiitis (Wegener's).

Authors:  Mikkel Faurschou; Niels Obel; Bo Baslund
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-12       Impact factor: 4.794

View more
  1 in total

1.  Increased risk of venous thromboembolism in patients with granulomatosis with polyangiitis: A population-based study.

Authors:  Shelby Marozoff; Alice Mai; Natasha Dehghan; Eric C Sayre; Hyon K Choi; J Antonio Aviña-Zubieta
Journal:  PLoS One       Date:  2022-06-17       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.